Pfizer’s mRNA flu vaccine met both primary endpoints in the 18- to 64-year-old population in an ongoing Phase III trial, the company announced on Tuesday morning. However, executives are no longer shooting for a 2024 launch.
While Pfizer initially pegged a possible 2024 launch for its standalone mRNA flu vaccine, that timing has been pushed to “after 2024.” Its next-generation mRNA flu and Covid-19 combination vaccine is expected to launch in 2025, CEO Albert Bourla said in prepared remarks ahead of the company’s third-quarter earnings call.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
Pfizer details mRNA flu vaccine data, but revises timeline - Endpoints News
Read More
Bagikan Berita Ini
0 Response to "Pfizer details mRNA flu vaccine data, but revises timeline - Endpoints News"
Post a Comment